By Fineline Cube 
UK-based pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) announced the launch of the Linked by Lupus: Optimal Care Initiative, a program designed to support individuals affected by lupus, particularly those with systemic lupus erythematosus (SLE) and lupus nephritis (LN).
Program Focus
The initiative calls for community-driven proposals focused on improving early diagnosis and recognition of lupus symptoms. It aims to enhance awareness and access to evidence-based treatment options and advance patient-provider communication about lupus.
Funding Commitment
GSK has committed up to USD 1 million in funding to support national, state, and local nonprofit organizations as well as community groups dedicated to lupus care.-Fineline Info & Tech